The problem of waste in cancer therapeutics
More than $100 billion is spent each year on cancer drugs worldwide to improve the lives of men and women diagnosed with cancer.1 However, with an average efficacy rate of only 25%,2 most patients do not experience significant clinical benefit—resulting in more than $75 billion in annual spending on ineffective treatments.
Watch: How Genomic Health is leading the way toward smarter cancer care with precision medicine.
The Oncotype IQ Platform and our proven cost savings
Precision medicine offers the opportunity to solve this problem. Genomic Health delivers on the promise of precision medicine, having tested over 1 million patients in over 90 countries, and saving the healthcare system an estimated $5 billion in the United States alone.3 For over a decade we’ve provided patients with personalized biological information that helps them get the right treatment at the right time, and to avoid unnecessary treatments and their side effects. Our robust Oncotype IQ Genomic Intelligence Platform includes a suite of tissue-based tests as well as liquid biopsy tests that answer specific and critical questions throughout the cancer journey.
Oncotype DX for breast cancer patients
The Oncotype DX test for breast cancer is the best example of precision medicine for cancer patients. It addresses the problem that only about 4 in 100 women who are diagnosed with early stage breast cancer benefit from chemotherapy.4
Oncotype DX is the only genomic test proven to identify patients who will likely benefit from chemotherapy—as well as those who won’t, so they can confidently and safely avoid unnecessary side effects. With an impressive body of clinical evidence, Oncotype DX is recognized as the standard of care in early breast cancer.
The healthcare savings made possible by Oncotype DX have been documented in pharmacoeconomic studies.
- The Oncotype DX Breast Recurrence Score results can save up to $49 million in short term health care costs for women with early-stage breast cancer5
- Ductal carcinoma in situ (DCIS): Investigators predicted an average savings of $1,000 per patient.6
Oncotype DX for prostate cancer patients
For the 135,000 men who are diagnosed with clinically low-risk prostate cancer each year, the Oncotype Genomic Prostate Score estimates cancer risk and can guide decisions about need for immediate treatment.
Alternatively, for men with a favorable prognosis, the test can help them confidently choose active surveillance, and avoid the serious side effects of surgery or radiation. Oncotype DX is estimated to yield a net savings of over $2,000 per patient by decreasing unnecessary invasive treatment,7 and poised to save the US healthcare system well over $100 million each year of direct costs.8
Delivering on the promise of precision medicine
Looking ahead, we will continue to expand our Oncotype IQ Genomic Intelligence Platform through product development and strategic partnerships—all with mission of delivering precision medicine to make cancer care smarter.